Genesis - Latest News [Page 3]

Students Sacrifice Summer Sun for Science Forum

Sunday, 11 January 2004, 3:49 pm | Genesis

A record 144 of New Zealand’s sharpest young scientific minds are gathering in Auckland this weekend for the fifteenth annual Genesis Research and Development Science and Technology Forum. More >>

Genesis Research Provide Update On PVAC™ Treatment

Tuesday, 23 December 2003, 5:29 pm | Genesis

Auckland and Seattle, December 22, 2003 – Genesis Research and Development Corporation Ltd (NZX/ASX: GEN) and Corixa Corporation (Nasdaq: CRXA) today announced that the companies have discontinued the development of PVAC™, a product candidate for the ... More >>

Plant Science Business To AgriGenesis Biosciences

Wednesday, 17 December 2003, 11:07 am | Genesis

Genesis Research and Development Corporation (NZX/ASX: GEN) confirms that it has completed the transfer of its plant sciences business to a wholly owned subsidiary, AgriGenesis Biosciences Limited, which is now trading as an independently managed ... More >>

Phase II Trial of AVAC™ in Childhood Eczema

Wednesday, 10 September 2003, 12:24 am | Genesis

Genesis Research and Development Corporation (NZX/ASX: GEN) and its partner, London-based biopharmaceutical company SR Pharma (LSE: SPA) today announced the commencement of a randomised, placebo-controlled Phase II trial of AVAC™ in paediatric atopic dermatitis ... More >>

Genesis Research Announces Half Year Result

Wednesday, 6 August 2003, 11:47 am | Genesis

Genesis Research and Development Corporation Ltd (NZX/ASX: GEN) today announced its financial results for the six-month period to June 30. More >>

Genesis Research Appoints Chief Executive

Tuesday, 5 August 2003, 4:46 pm | Genesis

Genesis Research and Development Corporation Limited (NZX/ASX: GEN) today announced the appointment of Dr Peter Lee, an expatriate New Zealander, as Chief Executive of AgriGenesis Biosciences limited, its plant science subsidiary that was announced ... More >>

Genesis Research and EvoGenix To Collaborate

Monday, 14 April 2003, 2:48 pm | Genesis

Genesis Research and Development Corporation Limited (NZSE/ASX: GEN) and EvoGenix Pty Limited today announced the signing of a collaboration agreement to undertake a joint research and development program to discover novel anti-inflammatory drugs. More >>

Genesis Awarded $800,000 Grant

Wednesday, 5 March 2003, 3:15 pm | Genesis

Technology New Zealand has awarded Genesis Research and Development Corporation Limited (NZSE /ASX: GEN) a technology development grant of almost $800,000 over two years to support the development of new gene discovery software and capitalise on ... More >>

Phase I Safety Study in Atopic Dermatitis

Wednesday, 5 March 2003, 3:13 pm | Genesis

Genesis Research and Development Corporation (NZSE / ASX: GEN) and SR Pharma plc (LSE: SPA) today announced the successful completion of a Phase I safety study of AVAC™ for the treatment of atopic dermatitis (also known as eczema) in children, ... More >>

Genesis Research Maintains Cash Reserves of $36.3m

Friday, 7 February 2003, 12:43 am | Genesis

Genesis Research and Development Corporation Limited [NZSE & ASX: GEN] today announced that it finished the 2002 year with cash reserves of $36.3 million, sufficient to fund its current and planned research and trial programmes for the foreseeable future. More >>

Keen Young Kiwi Scientists Head Up To The Forum

Friday, 10 January 2003, 11:42 am | Genesis

The keenest science students from around New Zealand are gathering in Auckland this weekend for the 14th annual Genesis Research National Science and Technology Forum. More >>

Phase II trial of SRP299 in childhood eczema

Tuesday, 26 November 2002, 10:09 am | Genesis

Genesis Research and Development Corporation (NZSE/ASX: GEN) and London-based biopharmaceutical company SR Pharma (LSE: SPA), today announced the start of a phase II, randomised, placebo-controlled, trial of SRP299 (a killed Mycobacterium vaccae suspension) for ... More >>

Genesis Establishes High Level Development Team

Thursday, 26 September 2002, 1:19 pm | Genesis

Genesis Research and Development Corporation Ltd (NZSE/ASX: GEN) today announced that it has enhanced its commercial capability by establishing a strategic development unit. The unit will be charged with identifying programmes, processes and technologies ... More >>

Five Days Left For Next Generation Scientists

Monday, 5 August 2002, 1:57 pm | Genesis

Auckland, 5 August 2002 – Kiwi Year 12 students with a thirst for scientific knowledge have only until Friday to register for New Zealand’s premier international student science programme. Students wanting to apply for the Genesis Research National Science ... More >>

Genesis Research Announces Half Year Result

Monday, 29 July 2002, 10:05 am | Genesis

Genesis Research and Development Corporation Ltd (NZSE / ASX: GEN) today announced results for the six month period to June 30. More >>

Clinical Trial of PVAC™ with UVB in New Zealand

Friday, 28 June 2002, 2:47 pm | Genesis

Randomised, Blinded and Controlled Trial to Evaluate Improvement of Disease Severity in Patients with Mild to Moderate Psoriasis More >>

Genesis Research Confirms Full Listing on ASX

Friday, 28 June 2002, 2:46 pm | Genesis

Genesis Research and Development Corporation Ltd (NZSE/ASX: GEN) today announced that it has satisfied all Australian Stock Exchange (ASX) requirements and will transfer from a Foreign Exempt listing on ASX to a Full Listing effective 1st July 2002. Genesis ... More >>

Genesis Announces New U.S. Clinical Trial of PVAC™

Friday, 7 June 2002, 10:52 am | Genesis

Genesis Research and Development Corporation Ltd (NZSE/ASX: GEN) today announced that Corixa Corporation has initiated an additional U.S. clinical study designed to evaluate the potential effectiveness of PVAC™ treatment for patients with mild ... More >>

Results Of Safety Study In Atopic Dermatitis

Friday, 3 May 2002, 11:50 am | Genesis

Genesis Research and Development Corporation today announced that it had completed a Phase I safety study of AVAC™ for the treatment of atopic dermatitis (also known as eczema) in adults, which showed that AVAC™ was safe and well tolerated. This first ... More >>

Genesis Appoints Vice-President for Health Science

Wednesday, 27 March 2002, 9:57 am | Genesis

Genesis Research and Development Corporation today announced the appointment of Dr Benjamin Twombly as Vice President of Business Development, responsible for expanding the company’s Health Sciences commercial activities in North America. More >>

   

 
 
 
 
 

LATEST HEADLINES

  • PARLIAMENT
  • POLITICS
  • REGIONAL